Digital Sponsored Antiviral development in the age of AI: From pre-IND to earl... hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.
News Aicuris acquisition delivers new drug for Asahi Kasei Asahi Kasei's $920m takeover of Germany's Aicuris in April has paid off with FDA approval for the herpes simplex virus drug at the heart of the deal.
News England close to eliminating hep C thanks to treatment drive England is on track to be one of the first countries in the world to eliminate hepatitis C, thanks to a national diagnosis and treatment programme.
News Island Pharma drug cleared for Bundibugyo Ebola use Island Pharma has been granted the approvals needed to allow compassionate use of its antiviral galidesivir in the Bundibugyo Ebola outbreak.
News As Ebola deaths climb, search begins for vaccine The WHO has held a closed expert meeting to identify potential vaccines for the Bundibugyo species of Ebola and fast-track clinical trials.
News Asahi Kasei buys antiviral firm Aicuris for €780m Asahi Kasei has agreed to buy Germany's Aicuris for around $920m, adding an antiviral drug it hopes will help drive its 2030 pharma sales to $1.9bn.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.